B+
Bull case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
RNA
Atrium TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
IND clearance, Corventis initiation, and a $15 million BMS collaboration milestone support execution. Atrium reported $263.9 million of cash, equivalents and short-term investments at June 30 and said resources, including the August milestone, should fund planned operations through mid-2028 [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.4.
What can break
ATR 1086 IND timing and future collaboration milestones remain uncertain [#SEC-8K-2026-08-13].
Momentum
5
Value
58
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $15.00 · Bear $4.00Analysis 2026-09-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $25.00
Why
Momentum5 · Δ7d +2.0
Value58 · Δ7d -0.1
Sentiment69 · Δ7d -7.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -7.4.
Contradictions & invalidation
- • ATR 1086 IND timing and future collaboration milestones remain uncertain [#SEC-8K-2026-08-13].
- • Corventis enrollment may miss the year-end 2026 expectation [#SEC-8K-2026-08-13].
- • ATR 1072 has no demonstrated clinical efficacy; enrollment delays, safety findings or inconclusive data could substantially impair the thesis.
Catalyst clock
2026-12-31
First participant in Corventis
Lead driver: Sentiment · See AI snapshot
Momentum
5
8% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
+2.9
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
69
45% active weight
Current posture
7d trendSoftening
Δ7d
-7.4
Δ21d
-18.0
Why this grade
Composite grade B. Momentum 4.6 / Value 58.2 / Sentiment 69.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$182.66M
Beta
0.93
Shares Out
22.28M
P/E (TTM) · Derived
-2.8
P/S (TTM)
520.38
P/FCF (TTM) · Derived
-1.81
Rev YoY
-21.9%
EPS YoY
+56.7%
Gross Margin
-
Op Margin
-2934.9%
Net Debt
$3.67M
Current Ratio
8.73
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data